These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24737044)

  • 1. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
    Liang C; Li YY
    Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Pim kinases in multiple myeloma.
    Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
    Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors.
    Mori M; Tintori C; Christopher RS; Radi M; Schenone S; Musumeci F; Brullo C; Sanità P; Delle Monache S; Angelucci A; Kissova M; Crespan E; Maga G; Botta M
    ChemMedChem; 2013 Mar; 8(3):484-96. PubMed ID: 23436791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIM1 kinase as a target for cancer therapy.
    Merkel AL; Meggers E; Ocker M
    Expert Opin Investig Drugs; 2012 Apr; 21(4):425-36. PubMed ID: 22385334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
    Yang Q; Chen LS; Gandhi V
    Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Pim kinases for cancer treatment: opportunities and challenges.
    Le BT; Kumarasiri M; Adams JR; Yu M; Milne R; Sykes MJ; Wang S
    Future Med Chem; 2015; 7(1):35-53. PubMed ID: 25582332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pim kinase inhibitors: a survey of the patent literature.
    Morwick T
    Expert Opin Ther Pat; 2010 Feb; 20(2):193-212. PubMed ID: 20100002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
    Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
    Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials.
    Jeyapal GP; Chandrasekar MJN; Krishnasamy R; Selvaraj J; Mohammad M; Nanjan MJ
    Anticancer Agents Med Chem; 2018; 18(8):1100-1114. PubMed ID: 29384063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy.
    Panchal NK; Sabina EP
    Life Sci; 2020 Aug; 255():117866. PubMed ID: 32479955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.
    Pierre F; Stefan E; Nédellec AS; Chevrel MC; Regan CF; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Anderes K; Ryckman DM
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6687-92. PubMed ID: 21982499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase.
    Sliman F; Blairvacq M; Durieu E; Meijer L; Rodrigo J; Desmaële D
    Bioorg Med Chem Lett; 2010 May; 20(9):2801-5. PubMed ID: 20363627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
    Akué-Gédu R; Rossignol E; Azzaro S; Knapp S; Filippakopoulos P; Bullock AN; Bain J; Cohen P; Prudhomme M; Anizon F; Moreau P
    J Med Chem; 2009 Oct; 52(20):6369-81. PubMed ID: 19788246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target.
    Rout AK; Dehury B; Parida SN; Rout SS; Jena R; Kaushik N; Kaushik NK; Pradhan SK; Sahoo CR; Singh AK; Arya M; Behera BK
    Int J Biol Macromol; 2024 Jun; 270(Pt 1):132030. PubMed ID: 38704069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
    Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
    Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
    Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
    Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
    Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
    Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives.
    Walhekar V; Bagul C; Kumar D; Muthal A; Achaiah G; Kulkarni R
    Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188725. PubMed ID: 35367531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.